- Home
- VISN vs ERAS Comparison
VISN vs ERAS Comparison
Compare VISN & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VISN | ERAS |
|---|---|---|
| Founded | 1976 | 2018 |
| Country | United States | United States |
| Employees | 4500 | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 4.0B |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | VISN | ERAS |
|---|---|---|
| Price | $12.46 | $18.72 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 12 |
| Target Price | ★ $21.00 | $14.25 |
| AVG Volume (30 Days) | ★ 6.0M | 5.5M |
| Earning Date | 04-30-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 36.23 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $9.44 | N/A |
| Revenue Next Year | $5.91 | N/A |
| P/E Ratio | $5.37 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.47 | $1.33 |
| 52 Week High | $19.91 | $24.28 |
Technical Indicators
Market Signals| Indicator | VISN | ERAS |
|---|---|---|
| Relative Strength Index (RSI) | 48.83 | 67.85 |
| Support Level | $12.31 | $12.36 |
| Resistance Level | $12.90 | $24.28 |
| Average True Range (ATR) | 0.38 | 1.20 |
| MACD | 0.02 | 0.22 |
| Stochastic Oscillator | 58.06 | 77.71 |
Price Performance
Historical ComparisonAbout VISN Vistance Networks Inc. Common Stock
Vistance Networks Inc operates in the communications technology sector, providing solutions designed to support the delivery and management of communications services. It serves customers globally through teams involved in product development, implementation, and customer support. The company designs and develops network infrastructure and connectivity solutions focused on reliability and performance. Its offerings include intelligent networking technologies intended to support evolving communication requirements.
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.